Segment Reporting - Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment (Details) - CODM [Member] - USD ($) |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment [Line Items] | ||
| Clinical Study Expense | $ 1,471,100 | $ 7,960,600 |
| Other Research Expense | 1,118,400 | 1,831,000 |
| Manufacturing and Drug Storage Expense | 2,784,200 | 155,600 |
| Compensation Expense | 1,674,500 | 933,500 |
| Stock-based Compensation Expense | 1,039,600 | 1,070,300 |
| Total Research and Development Expense | $ 8,087,800 | $ 11,951,000 |
| X | ||||||||||
- Definition Amount of pre-clinical expenses. No definition available.
|
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for employee benefit and equity-based compensation. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate costs incurred in the production of goods for sale. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|